Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
P/E Ratio
--
P/B Ratio
8.65
Industry P/E
--
Debt to Equity
0.91
ROE
-1.53 %
ROCE
-109.53 %
Div. Yield
0 %
Book Value
0.13
EPS
-0.54
CFO
$-29.51 Mln
EBITDA
$-58.96 Mln
Net Profit
$-64.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
IRIDEX (IRIX)
| -27.38 | 28.42 | -25.61 | -58.50 | -33.07 | -6.53 | -18.99 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
IRIDEX (IRIX)
| -39.96 | 39.80 | -67.10 | 143.43 | 12.56 | -52.55 | -38.16 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.93 | 10,562.04 | 12.43 | 12.69 | |
| 72.80 | 10,050.19 | 97.07 | 2.52 | |
| 163.74 | 8,533.78 | -- | -25.23 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo... G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx, a laser photocoagulation system that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. Address: 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043 Read more
President, CEO & Director
Mr. David I. Bruce
President, CEO & Director
Mr. David I. Bruce
Headquarters
Mountain View, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of IRIDEX Corporation (IRIX) stood at $ 29 Mln as on 31-Dec-24
The share price of IRIDEX Corporation (IRIX) is $1.22 (NASDAQ) as of 25-Apr-2025 16:00 EDT. IRIDEX Corporation (IRIX) has given a return of -33.07% in the last 3 years.
IRIDEX Corporation (IRIX) has a market capitalisation of $ 20 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of IRIDEX Corporation (IRIX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the IRIDEX Corporation (IRIX) and enter the required number of quantities and click on buy to purchase the shares of IRIDEX Corporation (IRIX).
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx, a laser photocoagulation system that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. Address: 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043
The CEO & director of Mr. David I. Bruce. is IRIDEX Corporation (IRIX), and CFO & Sr. VP is Mr. David I. Bruce.
There is no promoter pledging in IRIDEX Corporation (IRIX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| IRIDEX Corporation (IRIX) | Ratios |
|---|---|
|
Return on equity(%)
|
-153.37
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-18.31
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of IRIDEX Corporation (IRIX) was $0 Mln.
$0.06
(
